Richa Gupta, MD
Advanced Heart Failure and Transplant Cardiology · Nashville, TNNPI 1649541061
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $32,000 of the $46,485 with a category attached, or 68.8%. Cvrx, Inc. accounts for 91.8% of it on its own, with 8 other manufacturers making up the rest.
Across 115 payments — averaging $404.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cvrx, Inc.$43K
- Abbott$2K
- Abiomed$468
- Ancora Heart, Inc.$279
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$153
- Novo Nordisk$145
- plus $298 from 3 others
What the payments were for
- Consulting fees$32,00069%
- Travel & lodging$6,23113%
- Food & beverage$8,25418%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cvrx, Inc. | 76 | $42,672 |
| Abbott | 25 | $2,471 |
| Abiomed | 6 | $468 |
| Ancora Heart, Inc. | 1 | $279 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $153 |
| Novo Nordisk | 2 | $145 |
| Medtronic | 1 | $130 |
| Johnson & Johnson | 1 | $105 |
| Kestra Medical Technology Services, Inc. | 1 | $62 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Barostim Neo System$41,309
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$1,973
- Impella$383
- AccuCinch$279
- THORATEC HEARTMATE II, LVAS IMPLANT KIT$134
- LINQ II$130
- Wegovy$121
- CARDIOMEMS$109
- LifeVest$107
- XARELTO$105
How this compares
$46,485 in reported general payments places this provider in the 85th percentile of 28 advanced heart failure and transplant cardiology providers in Tennessee.
See all advanced heart failure and transplant cardiology providers in Tennessee →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 134 | $214,120 |
| JardianceEmpagliflozin | 62 | $88,915 |
| EliquisApixaban | 23 | $33,807 |
| Cefepime Hcl | 11 | $12,824 |
| OzempicSemaglutide | 11 | $11,713 |
| Digoxin | 18 | $3,563 |
| Metoprolol Succinate | 57 | $1,300 |
| Torsemide | 35 | $1,085 |
| Rosuvastatin Calcium | 40 | $904 |
| Spironolactone | 96 | $731 |
| Atorvastatin Calcium | 68 | $682 |
| Losartan Potassium | 54 | $525 |
| Carvedilol | 66 | $469 |
| Amlodipine Besylate | 38 | $409 |
| Amiodarone Hcl | 14 | $353 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $145 | $11,71311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 28 advanced heart failure and transplant cardiology providers in Tennessee.
Other advanced heart failure and transplant cardiology in Nashville
- Jonathan MenachemNashville$79K
- Matthew DeshazoNashville$38K
- Lynne StevensonNashville$25K
- Warren StriblingNashville$23K
- Mark AaronNashville$13K
- John BiglaneNashville$9K
- Jeremy BrooksbankNashville$9K
- Ashley BockNashville$8K
- Zachary Il'giovineNashville$6K
- Andrew McRaeNashville$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.